Macquarie Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Macquarie Group’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-110,000	Closed	-$776K	–	1020
2025 Q3	$776K	Hold	110,000	–	–	﹤0.01%	1361
2025 Q2	$715K	Hold	110,000	–	–	﹤0.01%	1423
2025 Q1	$872K	Hold	110,000	–	–	﹤0.01%	1407
2024 Q4	$1.39M	Hold	110,000	–	–	﹤0.01%	1289
2024 Q3	$1.53M	Sell	110,000 -603	-0.5%	-$8.6K	﹤0.01%	1302
2024 Q2	$1.52M	Buy	110,603 +603	+0.5%	+$8.82K	﹤0.01%	1295
2024 Q1	$1.82M	Hold	110,000	–	–	﹤0.01%	1246
2023 Q4	$1.61M	Hold	110,000	–	–	﹤0.01%	1286
2023 Q3	$1.35M	Hold	110,000	–	–	﹤0.01%	1268
2023 Q2	$1.31M	Hold	110,000	–	–	﹤0.01%	1300
2023 Q1	$1.47M	Hold	110,000	–	–	﹤0.01%	1259
2022 Q4	$2.37M	Hold	110,000	–	–	﹤0.01%	1162
2022 Q3	$2.2M	Hold	110,000	–	–	﹤0.01%	1193
2022 Q2	$1.97M	Buy	+110,000	New	+$1.14M	﹤0.01%	1300

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's DAWN Position: Q4 2025 in Review

Macquarie Group sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 110,000 shares — an estimated $776K sold.

Macquarie Group first reported a position in DAWN in Q2 2022 and held it in 14 quarters. The position peaked at $2.37M in Q4 2022. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

Macquarie Group reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 110,000 Day One Biopharmaceuticals shares in Q4 2025, an estimated $776K.
Macquarie Group first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 14 quarters.
Macquarie Group's Day One Biopharmaceuticals position peaked at $2.37M in Q4 2022.
183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.